A new market research report on the Global Beta-lactam
and Beta-lactamase Inhibitors market has introduced by KD Market
Insights. The report is dedicated to in-depth industry analysis of the
global Beta-lactam and Beta-lactamase Inhibitors market. The Global Beta-lactam and Beta-lactamase
Inhibitors analysis is broken down on
different segmentation levels including
Market By Drug Class, By Disease, By Route of
Administration.
The global beta-lactam and beta-lactamase inhibitors
market size was $27,126 million in 2018, and is projected
to reach $34,170 million by 2028, growing at a CAGR of 2.3% from
2019 to 2028.
Beta-lactam
and beta-lactamase inhibitors is a most important type of antibacterial agent
used for fighting bacterial infections. In addition, these are used to kill or
prevent the growth of microorganisms. Based on the molecular structure,
beta-lactam and beta-lactamase inhibitors are drug classified into penicillin,
cephalosporin, carbapenem, monobactam, and combination.
There is an increase in the demand for beta-lactam and
beta-lactamase inhibitors, owing to increased consumption in low- and
middle-income countries (LMICs) and rise in prevalence of infectious diseases.
In addition, development of novel approaches for new beta-lactam and
beta-lactamase inhibitors for treating bacterial infections and many clinical
trials further drive the market growth. However, development of antibiotic
resistance, driven by misuse of beta-lactam and beta-lactamase inhibitors and the
time taken for the regulatory approval is projected to impede the market
growth. On the contrary, discovery of advanced prospect molecules and novel
combination therapies to treat antibiotic-resistant microbial infections are
expected to offer significant profitable opportunities for the market players.
The
global beta-lactam
and beta-lactamase inhibitors market is segmented based on
drug class, disease, route of administration, and region. Based on the drug
class, the market is classified into penicillin, cephalosporin, carbapenem,
monobactam, and combination. Combination segment is further categorized into
penicillin/beta lactamase inhibitors, cephalosporins/beta lactamase inhibitors,
and carbapenems/beta lactamase inhibitors. Depending on the disease segment,
the market is divided into urinary tract infection (excluding cUTI),
respiratory infection, skin infection, complicated urinary tract infection
(cUTI), complicated intra-abdominal infections (cIAI), nosocomial pneumonia,
blood stream infection, and other diseases. Nosocomial pneumonia segment is
further divided into hospital acquired pneumonia, ventilator associated
pneumonia, and other nosocomial pneumonia. Based on route of administration,
the market is classified into oral, intravenous, and others. Based on region,
the market is studied across North America, Europe, Asia-Pacific, and LAMEA.
KEY BENEFITS FOR STAKEHOLDERS
-
This report provides a detailed quantitative analysis of the current market
trends and future estimations from 2019 to 2028, which assists to identify the
prevailing market opportunities.
- An in-depth analysis of various regions is anticipated to provide a detailed understanding of the current trends to enable stakeholders to formulate region-specific plans.
- A comprehensive analysis of the factors that drive and restrain the growth of the global beta-lactam and beta-lactamase inhibitors market is provided.
- An extensive analysis of various regions provides insights that allow companies to strategically plan their business moves.
- An in-depth analysis of various regions is anticipated to provide a detailed understanding of the current trends to enable stakeholders to formulate region-specific plans.
- A comprehensive analysis of the factors that drive and restrain the growth of the global beta-lactam and beta-lactamase inhibitors market is provided.
- An extensive analysis of various regions provides insights that allow companies to strategically plan their business moves.
KEY MARKET SEGMENTS
By Drug Class
- Penicillin
- Cephalosporin
- Carbapenem
- Monobactam
- Combination
- - - Penicillin/Beta Lactamase Inhibitors
- - - Cephalosporins/Beta Lactamase Inhibitors
- - - Carbapenems/Beta Lactamase Inhibitors
- Penicillin
- Cephalosporin
- Carbapenem
- Monobactam
- Combination
- - - Penicillin/Beta Lactamase Inhibitors
- - - Cephalosporins/Beta Lactamase Inhibitors
- - - Carbapenems/Beta Lactamase Inhibitors
By Disease
- Urinary Tract Infection (excluding cUTI)
- Respiratory Infection
- Skin Infection
- Complicated Urinary Tract Infection (cUTI)
- Complicated Intra-Abdominal Infections (cIAI)
- Nosocomial Pneumonia
- - - Hospital Acquired Pneumonia
- - - Ventilator Associated Pneumonia
- - - Other Nosocomial Pneumonia
- Blood Stream Infection
- Other Diseases
- Urinary Tract Infection (excluding cUTI)
- Respiratory Infection
- Skin Infection
- Complicated Urinary Tract Infection (cUTI)
- Complicated Intra-Abdominal Infections (cIAI)
- Nosocomial Pneumonia
- - - Hospital Acquired Pneumonia
- - - Ventilator Associated Pneumonia
- - - Other Nosocomial Pneumonia
- Blood Stream Infection
- Other Diseases
By Route of Administration
- Oral
- Intravenous
- Others
- Oral
- Intravenous
- Others
By Region
North
America
- U.S.
- Canada
- Mexico
Europe
- Germany
- France
- Spain
- Italy
- UK
- Rest of Europe
Asia-Pacific
- Japan
- India
- China
- South Korea
- Thailand
- Taiwan
- Vietnam
- Rest of Asia-Pacific
LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest of LAMEA
- U.S.
- Canada
- Mexico
Europe
- Germany
- France
- Spain
- Italy
- UK
- Rest of Europe
Asia-Pacific
- Japan
- India
- China
- South Korea
- Thailand
- Taiwan
- Vietnam
- Rest of Asia-Pacific
LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest of LAMEA
KEY MARKET PLAYERS
-
Abbott Laboratories
- Allergan Plc.
- F. Hoffmann-La Roche Ltd.
- GlaxoSmithKline plc
- Merck & Co. Inc.
- Mylan N.V.
- Novartis International AG (Sandoz)
- Pfizer Inc.
- Sanofi
- Teva Pharmaceutical Industries Ltd.
- Allergan Plc.
- F. Hoffmann-La Roche Ltd.
- GlaxoSmithKline plc
- Merck & Co. Inc.
- Mylan N.V.
- Novartis International AG (Sandoz)
- Pfizer Inc.
- Sanofi
- Teva Pharmaceutical Industries Ltd.
Access Complete Research Report with TOC @ https://www.kdmarketinsights.com/product/beta-lactam-and-beta-lactamase-inhibitors-market-amr
Table of Content
Chapter 1: Introduction
1.1.
Report Description
1.2. Key Benefits For Stakeholders
1.3. Key Market Segments
1.2. Key Benefits For Stakeholders
1.3. Key Market Segments
1.3.1.
List of Key Players Profiled In The Report
1.4.
Research Methodology
1.4.1.
Secondary Research
1.4.2. Primary Research
1.4.3. Analyst Tools And Models
1.4.2. Primary Research
1.4.3. Analyst Tools And Models
Chapter 2: Executive Summary
2.1.1.
Cxo Perspective
Chapter 3: Market Overview
3.1.
Market Definition And Scope
3.2. Key Findings
3.2. Key Findings
3.2.1.
Top Investment Pockets
3.3.
Top Winning Strategies
3.3.1.
Top Player Positioning, 2018
3.4.
Porter’S Five Forces Analysis
3.5. Market Dynamics
3.5. Market Dynamics
3.5.1.
Drivers
3.5.1.1.
Increased Consumption In Low And Middle-Income Countries (Lmics)
3.5.1.2. Rise In Prevalence of Infectious Diseases
3.5.1.3. Development of Novel Approaches For New Beta-Lactam And Beta-Lactamase Inhibitors For Treating Bacterial Infections
3.5.1.2. Rise In Prevalence of Infectious Diseases
3.5.1.3. Development of Novel Approaches For New Beta-Lactam And Beta-Lactamase Inhibitors For Treating Bacterial Infections
3.5.2.
Restraints
3.5.2.1.
Development of Beta-Lactam Resistance
3.5.2.2. Longer Approval Time By The Regulatory Bodies
3.5.2.2. Longer Approval Time By The Regulatory Bodies
3.5.3.
Opportunity
3.5.3.1.
Discovery of Advanced Prospect Molecules And Novel Combination Therapies To
Treat Antibiotic-Resistant Microbial Infections
3.6.
Antimicrobial Resistance And Countermeasure Trends
3.6.1.
Countermeasure Trends
Chapter 4: Beta-Lactam And Beta
Lactamase Inhibitors Market, By Drug Class
4.1.
Overview
4.1.1.
Market Size And Forecast
4.2.
Penicillin
4.2.1.
Key Market Trends And Growth Opportunities
4.2.2. Market Size And Forecast, By Region
4.2.3. Market Analysis, By Country
4.2.2. Market Size And Forecast, By Region
4.2.3. Market Analysis, By Country
4.3.
Cephalosporin
4.3.1.
Key Market Trends And Growth Opportunities
4.3.2. Market Size And Forecast, By Region
4.3.3. Market Analysis, By Country
4.3.2. Market Size And Forecast, By Region
4.3.3. Market Analysis, By Country
4.4.
Carbapenem
4.4.1.
Key Market Trends And Growth Opportunities
4.4.2. Market Size And Forecast, By Region
4.4.3. Market Analysis, By Country
4.4.2. Market Size And Forecast, By Region
4.4.3. Market Analysis, By Country
4.5.
Monobactam
4.5.1.
Key Market Trends And Growth Opportunities
4.5.2. Market Size And Forecast, By Region
4.5.3. Market Analysis, By Country
4.5.2. Market Size And Forecast, By Region
4.5.3. Market Analysis, By Country
4.6.
Combination
4.6.1.
Key Market Trends And Growth Opportunities
4.6.2. Market Size And Forecast, By Type
4.6.2. Market Size And Forecast, By Type
4.6.2.1.
Penicillin/Beta Lactamase Inhibitors
4.6.2.1.1.
Market Size And Forecast
4.6.2.2.
Cephalosporins/Beta Lactamase Inhibitors
4.6.2.2.1.
Market Size And Forecast
4.6.2.3.
Carbapenems/Beta Lactamase Inhibitors
4.6.2.3.1.
Market Size And Forecast
4.6.3.
Market Size And Forecast, By Region
4.6.4. Market Analysis, By Country
4.6.4. Market Analysis, By Country
Chapter 5: Beta-Lactam And Beta
Lactamase Inhibitors Market, By Disease
5.1.
Overview
5.1.1.
Market Size And Forecast
5.2.
Urinary Tract Infection (Excluding Cuti)
5.2.1.
Market Size And Forecast, By Region
5.2.2. Market Analysis, By Country
5.2.2. Market Analysis, By Country
5.3.
Respiratory Infection
5.3.1.
Market Size And Forecast, By Region
5.3.2. Market Analysis, By Country
5.3.2. Market Analysis, By Country
5.4.
Skin Infection
5.4.1.
Market Size And Forecast, By Region
5.4.2. Market Analysis, By Country
5.4.2. Market Analysis, By Country
5.5.
Complicated Urinary Tract Infection (Cuti)
5.5.1.
Market Size And Forecast, By Region
5.5.2. Market Analysis, By Country
5.5.3. Number of Patients, By Country
5.5.2. Market Analysis, By Country
5.5.3. Number of Patients, By Country
5.6.
Complicated Intra-Abdominal Infections (Ciai)
5.6.1.
Market Size And Forecast, By Region
5.6.2. Market Analysis, By Country
5.6.3. Number of Patients, By Country
5.6.2. Market Analysis, By Country
5.6.3. Number of Patients, By Country
5.7.
Nosocomial Pneumonia
5.7.1.
Market Size And Forecast, By Type
5.7.1.1.
Hospital Acquired Pneumonia
5.7.1.1.1.
Market Size And Forecast
5.7.1.2.
Ventilator Associated Pneumonia
5.7.1.2.1.
Market Size And Forecast
5.7.1.3.
Other Nosocomial Pneumonia
5.7.1.3.1.
Market Size And Forecast
5.7.2.
Market Size And Forecast, By Region
5.7.3. Market Analysis, By Country
5.7.4. Number of Patients, By Country
5.7.3. Market Analysis, By Country
5.7.4. Number of Patients, By Country
5.8.
Blood Stream Infection
5.8.1.
Market Size And Forecast, By Region
5.8.2. Market Analysis, By Country
5.8.3. Number of Patients, By Country
5.8.2. Market Analysis, By Country
5.8.3. Number of Patients, By Country
Continue @...
About Us:
KD Market
Insights offers a
comprehensive database of syndicated research studies, customized reports, and
consulting services. These reports are created to help in making smart, instant
and crucial decisions based on extensive and in-depth quantitative information,
supported by extensive analysis and industry insights. Our dedicated in-house
team ensures the reports satisfy the requirement of the client. We aim at
providing value service to our clients. Our reports are backed by extensive
industry coverage and is made sure to give importance to the specific needs of
our clients. The main idea is to enable our clients to make an informed
decision, by keeping them and ourselves up to date with the latest trends in
the market.
Contact Us:
KD Market Insights
150 State Street, Albany,
New York, USA 12207
+1 (518) 300-1215
Email: sales@kdmarketinsights.com
Website: www.kdmarketinsights.com
KD Market Insights
150 State Street, Albany,
New York, USA 12207
+1 (518) 300-1215
Email: sales@kdmarketinsights.com
Website: www.kdmarketinsights.com
This is dummy text. It is not meant to be read. Accordingly, it is difficult to figure out when to end it. But then, this is dummy text. It is not meant to be read. Period.
ConversionConversion EmoticonEmoticon